Dear readers of AMNOG Monitor,

‘Crisis-resistent healthcare is a fundamental part of a forward-looking security policy,’ said Federal Health Minister Nina Warken (CDU) at the Munich Security Conference (13-15 February). Germany and Europe must develop greater resilience in the healthcare sector in order to be better prepared for crisis situations such as defence emergencies, pandemics and supply chain disruptions, and to develop appropriate crisis plans.

The annual pharmaceutical conference (9–11 February) organised by Handelsblatt in Berlin also focused on the changed geopolitical situation and its impact on the German healthcare system. Thomas Müller (BMG) emphasised that the pharmaceutical and medical device industry is regarded by the German government as a key industry with high added value, whose economic framework conditions should be improved in international competition. The BMG is focusing primarily on the pharma dialogue, which is to be further developed into a comprehensive pharma strategy.

In the further development of the AMNOG, the dossiers should be simplified and, if necessary, AMNOG assessments with low patient numbers (<20) or low sales figures (<€20 million/year) are to be dispensed with altogether. The BMG also takes a critical view of the short-term change to the appropriate comparative treatment (ACT) – similar to the German Council of Economic Experts (SVR) in its report – and considers that the application-accompanying data collection (AbD) in its current form is not very effective and should, if necessary, be replaced by registers covering specific indications. The confidential reimbursement price has also not yet established itself as a successful model. Guard rails and combination discounts could possibly be replaced by simple compensation models. At the same time, there has been a dynamic development in expenditure within the statutory health insurance system (GKV) for years, affecting all main areas (hospitals, medicinal products, physicans honorars) equally.

Mrs Antje Haas (GKV-Spitzenverband) demanded that the promotion of Germany as a pharmaceutical location is a task for society as a whole and cannot be financed by the statutory health insurance system (GKV).

In February, there were nine new G-BA decisions (Fig. A), eight new procedures were initiated (Fig. B). The price changes are shown in Fig. C, and 14 EU HTA procedures have now been started (see link).
Ongoing EU HTA procedures (Excel)

Our newly programmed AMNOG monitor with integrated EU HTA features a number of innovations, e.g., a completely revised “intelligent search” function and other functions (e.g., guard rails, combination discount, confidential reimbursement amount), with more in the pipeline, e.g., MFN tracking. Take advantage of the opportunity to receive free training early on to benefit from the new possibilities.

New reimbursement prices of AMNOG products are available here.
EMA Positive Opinions for new drugs are shown here.

With this in mind, we look forward to continuing our cooperation with you.

Dr. Johannes Hankowitz
Munich, 20th February 2026